Evidence map›Paper›PMID 32830540›Full record

ArticleAmerican journal of physiology. Renal physiology2020

C57BL/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury.

Sophia M Sears, Cierra N Sharp, Austin Krueger, Gabrielle B Oropilla, Douglas Saforo, Mark A Doll, Judit Megyesi, Levi J Beverly, Leah J Siskind

Open access · greenAbstract readComparative Study
In one paragraph

Article in American journal of physiology. Renal physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Biomolecules · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sophia M SearsDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.ORCID 0000-0003-2396-5385
Cierra N SharpDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.
Austin KruegerDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.
Gabrielle B OropillaDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.
Douglas SaforoDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.
Mark A DollDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.
Judit MegyesiUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas.
Levi J BeverlyDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.
Leah J SiskindDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.
University of Louisville · USUniversity of Arkansas for Medical Sciences · US

Funding

Ubiquilins regulate EMT, migration and invasion of human lung cancerR01CA193220 · NCI · UNIVERSITY OF LOUISVILLE · PI BEVERLY, LEVI J · 2015 to 2019
$2.3M
The role of neutral ceramidase in acute kidney injury and its progression to chronic kidney disease.R01DK124112 · NIDDK · UNIVERSITY OF LOUISVILLE · PI SISKIND, LEAH J · 2020 to 2023
$2.1M
Role of macrophages in cisplatin-induced kidney injury and progression to chronic kidney diseaseF31DK126400 · NIDDK · UNIVERSITY OF LOUISVILLE · PI SEARS, SOPHIA MARIE · 2020 to 2021
$55k
HHS | NIH | National Cancer Institute (NCI) CA193220HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK124112HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK126400NCI NIH HHS R01 CA193220NIDDK NIH HHS F31 DK126400NIDDK NIH HHS R01 DK124112
6 · The paper itself

Abstract

C57BL/6 mice are one of the most commonly used mouse strains in research, especially in kidney injury studies. However, C57BL/6 mice are resistant to chronic kidney disease-associated pathologies, particularly the development of glomerulosclerosis and interstitial fibrosis. Our laboratory and others developed a more clinically relevant dosing regimen of cisplatin (7 mg/kg cisplatin once a week for 4 wk and mice euthanized at

Indexed as

CisplatinAcute Kidney InjuryAnimalsApoptosisChemokine CCL2Chemotaxis, LeukocyteDisease Models, AnimalEndoplasmic Reticulum StressFibrosisKidneyMacrophagesMaleMice, Inbred C57BLMonocytesNecrosisSignal TransductionCcl2 protein, mouseChemokine CCL2Cisplatinacute kidney injuryC-C motif chemokine ligand 2chronic kidney diseasecisplatinfibrosis

Identifiers

PMID32830540
PMCPMC7642885
OpenAlexW3080832910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.